US Pharm. 2010;35:50. 

Mylan Inc. announced that it has entered into agreements with Takeda Pharmaceutical Industries Ltd. related to two treatments for type 2 diabetes: Actoplus Met 15 mg/500 mg and 15 mg/850 mg (pioglitazone hydrochloride [HCl] and metformin HCl tablets) and Actos 15 mg, 30 mg, and 45 mg (pioglitazone HCl tablets). As aresult of the agreements, Mylan can market pioglitazone HCl and metformin HCl in the U.S. on December 14, 2012, and pioglitazone HCl in the U.S. on August 17, 2012.